Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Traws Pharma, Inc.TRAW · Entity 8032 | Chief Financial Officer | July 09, 2026 | July 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Traws Pharma, Inc.
Report date July 09, 2026 · Filed July 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2036-07-09 | Direct | 90,000 |
Reported balance
After 2026-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 90,000 · Balance 90,000 F1: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 15, 2026 00:22 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0002125562-26-000005 · form4-07152026_120746.xml · derivative · entry 1 Parker Charles Nolan · CIK 0002125562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-07-09 F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document |
| March 08, 2026 Filed Apr 8, 2026 18:47 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to buy) · Derivative | 104,544 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0002125562-26-000004 · form4-04082026_060446.xml · derivative · entry 4 Parker Charles Nolan · CIK 0002125562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,544 Underlying: Common Stock · 104,544 shares Expires 2036-03-08 F4 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document |
| December 12, 2025 Filed Apr 8, 2026 18:47 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to buy) · Derivative | 61,571 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0002125562-26-000004 · form4-04082026_060446.xml · derivative · entry 3 Parker Charles Nolan · CIK 0002125562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,571 Underlying: Common Stock · 61,571 shares Expires 2035-12-12 F3 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document |
| December 12, 2025 Filed Apr 8, 2026 18:47 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantCommon Stock | 15,393 | $0.00 | $0.00 |
DisclosureSEC source: 0002125562-26-000004 · form4-04082026_060446.xml · nonDerivative · entry 1 Parker Charles Nolan · CIK 0002125562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,393 F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis. Read SEC document |
| October 12, 2025 Filed Apr 8, 2026 18:47 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to buy) · Derivative | 32,406 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0002125562-26-000004 · form4-04082026_060446.xml · derivative · entry 2 Parker Charles Nolan · CIK 0002125562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,406 Underlying: Common Stock · 32,406 shares Expires 2035-10-12 F2 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.